Recent Updates — DRTS
Alpha Tau Medical Ltd. signed a memorandum of understanding with Samsung Medical Center (SMC) in Seoul, South Korea, to explore a potential clinical trial of its Alpha DaRT therapy for pancreatic cancer patients. The proposed study would be the company's first in South Korea and is subject to regulatory and ethics committee approvals. SMC is ranked number one in Korea and fifth globally in oncology. This partnership aims to expand the company's global pancreatic cancer program across Asia, North America, Europe, and the Middle East. Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company focused on developing alpha-radiation therapy for solid tumors.
The U.S. Food and Drug Administration has approved an Investigational Device Exemption (IDE) supplement for Alpha Tau Medical Ltd.'s REGAIN clinical trial, increasing the maximum enrollment from 10 to 20 patients at three authorized U.S. academic centers. The updated protocol expands eligibility to include patients with IDH-mutant grade 4 tumors and adds progression-free survival as a secondary endpoint alongside regular quality-of-life assessments. An interim analysis is scheduled six months after the fifth patient's treatment, which occurred in July 2026. Additionally, an abstract authored by principal investigator Dr. Joshua Palmer has been accepted for presentation at the Society for Neuro-Oncology (SNO) 2026 Annual Meeting in November. Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company focused on developing and commercializing the Alpha DaRT alpha-radiation therapy for solid tumors.
Alpha Tau Medical Ltd. announced on August 31, 2026, that it has completed patient enrollment in its multicenter IMPACT pilot study evaluating Alpha DaRT for newly diagnosed unresectable pancreatic cancer. The trial expanded enrollment three times from an initial target of 12 to a total of 48 treated patients across the United States, Canada, and Israel. Initial data is targeted for release in early 2027 to inform the design of a planned pivotal study. Alpha Tau Medical Ltd. operates in the oncology therapeutics industry, focusing on the research and development of alpha-radiation cancer therapy.
Alpha Tau Medical Ltd. reported positive clinical data for its Alpha DaRT therapy in combination with pembrolizumab for treating head and neck squamous cell carcinoma. The study met its pre-specified success criterion, demonstrating a 100% objective response rate and a median overall survival of 18.2 months among evaluable patients. Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company that develops Alpha DaRT technology for the treatment of solid tumors.
Alpha Tau Medical Ltd. announced the successful treatment of the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma in its ADMIRE study at Banner MD Anderson Cancer Center in Arizona. The company is a developer of photo-immunotherapy technology for own-purpose use in oncology.